Melanoma uveal de cuerpo ciliar / Uveal melanoma of ciliary body

RESUMEN El objetivo de este reporte de caso fue identificar las características de un nevo abultado conjuntival en una paciente femenina de 72 años de edad. Se muestran las pruebas complementarias realizadas para llegar al diagnóstico de melanoma conjuntival, que consiste en un tumor poco frecuente, el cual constituye el 2 por ciento de todos los tumores del ojo. Las células involucradas son los melanocitos del epitelio conjuntival. Un factor de riesgo para esta entidad puede ser la exposición a la luz ultravioleta; sin embargo, esto no está bien determinado. La mayoría de los casos se originan de una melanosis adquirida primaria (50-70 por ciento). La presentación más común es una lesión pigmentada, unilateral, elevada, gruesa, con vasos sanguíneos y áreas de melanosis a su alrededor. Su diagnóstico se realiza con la sospecha clínica que se confirma con el estudio histopatológico. El tratamiento en la actualidad es la excisión local, seguida de crioterapia, radioterapia o quimioterapia. La enfermedad matastásica ocurre en el 11 - 42 por ciento y en el 20 - 52 por ciento de los pacientes en un seguimiento de 5 y 10 años, respectivamente(AU)

ABSTRACT The objective of this case report is to describe the characteristics of a conjunctival bulging nevus in a 72-year-old female patient and the complementary tests that were performed to reach the diagnosis of conjunctival melanoma. Conjunctival melanoma is a rare tumor, which account for 2 percent of all eye tumors. The cells involved are the melanocytes of the conjunctival epithelium. A risk factor for this entity may be exposure to ultraviolet light. However, it has not been precisely described. Most cases originate from a primary acquired melanosis (50-70 percent). The most common presentation is a pigmented, unilateral, elevated, thick, lesion with blood vessels and areas of melanosis around it. Its diagnosis is made with the clinical suspicion confirmed with the histopathological study. Current treatment is local excision, followed by cryotherapy, radiotherapy, or chemotherapy. Metastatic disease occurs in 11-42 percent and 20-52 percent of patients in a 5-year and 10-year follow-up, respectively(AU)

Beta therapy with 90strontium as single modality therapy for canine squamous cell carcinoma in third eyelid / Betaterapia com estrôncio-90 como modalidade única de terapia para o carcinoma de células escamosas na terceira pálpebra em cães

The purpose was to evaluate the effectiveness of beta-radiation with strontium-90 as single modality treatment of canine third eyelid squamous cell carcinoma (SCC). Nine dogs diagnosed with third eyelid SCC were treated with strontium-90. Radiation therapy was administered in four fractions of 100cGy per site every four days and at a depth of 0.2cm (Strontium-90 build' up) in each fraction. Radiation with beta therapy was well tolerated in all animals with no occurrence of radiation induced cataracts. In all cases, there were increased signs of conjunctival inflammation around the mass, which subsided with topical anti-inflammatory. Two dogs required surgical treatment for local tumor recurrence at 150 days and 352 days. In the remaining seven cases, disease free interval ranged from 1239 days to 2555 days. Beta therapy using 90Sr may be a valid alternative for the treatment of third eyelid SCC in dogs.

O objetivo foi avaliar a eficácia da betaterapia com estrôncio-90 como modalidade única de tratamento em carcinomas de células escamosas (CEC) da terceira pálpebra de cães. Nove cães foram diagnosticados com CEC de terceira pálpebra, que foram tratados com estrôncio-90. A radioterapia foi administrada em quatro frações de 100cGy por local, a cada quatro dias e a uma profundidade de 0,2cm em cada fração. A betaterapia foi bem tolerada por todos os animais, sem ocorrência de catarata induzida pela radiação. Em todos os casos, houve um aumento dos sinais de inflamação da conjuntiva ao redor da neoformação, as quais cederam com o uso de anti-inflamatório tópico. Em dois cães houve a necessidade de tratamento cirúrgico, pois houve recorrência local do tumor aos 150 dias e aos 352 dias. Nos outros sete casos, o intervalo livre de doença variou entre 1.239 dias e 2.555 dias. Betaterapia usando 90Sr pode ser uma alternativa válida para o tratamento do CEC da terceira pálpebra em cães.

Carcinoma de células escamosas de la conjuntiva en adultos jóvenes inmunocompetentes / Squamous cell carcinoma of the conjunctiva observed in immunocompromised young adults

Se presentan dos casos de pacientes jóvenes VIH negativos, clínicamente inmunocompetentes, sin antecedentes de exposición actínica prolongada ni riesgo ocupacional, con diagnóstico de carcinoma escamoso de conjuntiva. Presentación inusual en este tipo de lesión que se caracteriza por ser más frecuente a partir de la sexta década de vida, en personas expuestas a las radiaciones ultravioletas o con inmunocompromiso. Su incidencia varía entre 0,13 y 1,9 casos por 100 000 habitantes y ocupa el segundo lugar en frecuencia de los tumores malignos oculares. Se realizó biopsia excisional amplia con margen de 5 mm, crioterapia en las márgenes de la lesión e injerto de membrana amniótica en ambos casos, sin recidiva tumoral en dos años de evolución(AU)

Two cases of young HIV-negative clinically immunocompromised patients, with no history of prolonged actinic exposure or occupational risk, and diagnosed with squamous cell carcinoma of the conjunctiva were presented. This is an unusual presentation in this type of injury that is more frequent after 60 years of age in people exposed to ultraviolet radiation or immunocompromised. Its incidence ranges 0,13 to 1,9 cases per 100,000 pop and ranks second infrequency of ocular malignancies. Excisional biopsy was performed with a 5 mm wide margin, cryotherapy in the borders of the lesion and amniotic membrane grafting were also performed in both cases, without tumor recurrence after two years of evolution(AU)